Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Exelixis, Inc. - Common Stock (NQ:EXEL)

42.14 -0.51 (-1.20%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Exelixis, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
News headline image
Is the Market Bullish or Bearish on Exelixis? ↗
 
Via Benzinga
News headline image
For those who appreciate growth without the sticker shock, EXELIXIS INC (NASDAQ:EXEL) is worth considering. ↗
Discover EXELIXIS INC, an undervalued growth gem. NASDAQ:EXEL is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing... 
Via Chartmill
News headline image
Does EXELIXIS INC (NASDAQ:EXEL) align with Mark Minervini’s trading strategy? ↗
A fundamental and technical analysis of (NASDAQ:EXEL): Why EXELIXIS INC (NASDAQ:EXEL) qualifies as a high growth stock. 
Via Chartmill
News headline image
Expert Outlook: Exelixis Through The Eyes Of 19 Analysts ↗
 
Via Benzinga
News headline image
Why EXELIXIS INC (NASDAQ:EXEL) is Poised for High Growth. ↗
Exploring high growth characteristics of EXELIXIS INC (NASDAQ:EXEL). A fundamental and technical analysis of (NASDAQ:EXEL). 
Via Chartmill
News headline image
EXELIXIS INC (NASDAQ:EXEL) qualifies as a high growth stock and is consolidating. ↗
Based on a technical and fundamental analysis of NASDAQ:EXEL we can say: EXELIXIS INC (NASDAQ:EXEL), a strong growth stock, setting up for a breakout. 
Via Chartmill
News headline image
Why EXELIXIS INC (NASDAQ:EXEL) qualifies as a high growth stock. ↗
A fundamental and technical analysis of (NASDAQ:EXEL): EXELIXIS INC (NASDAQ:EXEL) may be suited for high growth investing, we'll explore why in this article. 
Via Chartmill
News headline image
Peering Into Exelixis's Recent Short Interest ↗
 
Via Benzinga
News headline image
A Glimpse Into The Expert Outlook On Exelixis Through 21 Analysts ↗
 
Via Benzinga
News headline image
For those who appreciate growth without the sticker shock, EXELIXIS INC (NASDAQ:EXEL) is worth considering. ↗
EXELIXIS INC was identified as a growth stock that isn't overvalued. NASDAQ:EXEL is excelling in various growth indicators while maintaining a solid financial footing. 
Via Chartmill
News headline image
EXELIXIS INC (NASDAQ:EXEL) stands out as a stock that provides good value for the fundamentals it showcases. ↗
EXELIXIS INC is a hidden gem, featuring undervaluation and robust fundamentals. NASDAQ:EXEL showcases decent financial health and profitability, coupled with an attractive price. 
Via Chartmill
News headline image
The Smartest Biotech Stocks to Buy With $50 ↗
Via The Motley Fool
News headline image
FDA Approves Exelixis' Lead Cancer Drug Cabometyx For Expanded Use In Neuroendocrine Tumors ↗
Exelixis' Cabometyx gains FDA approval for advanced neuroendocrine tumors, while phase 3 data confirms sustained survival benefits in renal cancer. 
Via Benzinga
News headline image
Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis to Present Positive Preclinical Data Across Its Pipeline Portfolio for Advanced Cancers at AACR 2025
From Exelixis, Inc.
Via Business Wire
News headline image
Looking Into Exelixis's Recent Short Interest ↗
 
Via Benzinga
News headline image
EXELIXIS INC (NASDAQ:EXEL)—A High-Growth Stock Gearing Up for Its Next Upward Move. ↗
Based on a technical and fundamental analysis of NASDAQ:EXEL we conclude: EXELIXIS INC (NASDAQ:EXEL)—A High-Growth Stock Gearing Up for Its Next Upward Move. 
Via Chartmill
News headline image
What 25 Analyst Ratings Have To Say About Exelixis ↗
 
Via Benzinga
News headline image
Don't overlook EXELIXIS INC (NASDAQ:EXEL)—a stock with solid growth prospects and a reasonable valuation. ↗
Discover EXELIXIS INC, an undervalued growth gem. NASDAQ:EXEL is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing... 
Via Chartmill
News headline image
Is This The Beginning? Insights On Bearish Distribution Patterns ↗
Discover the characteristics of a bearish distribution and the criteria the S&P 500 needs for a technical rally. 
Via Talk Markets
Topics Stocks Stocks / Equities
News headline image
Exelixis to Webcast Fireside Chats at Upcoming Investor Conferences in March
From Exelixis, Inc.
Via Business Wire
News headline image
This Conagra Brands Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday ↗
 
Via Benzinga
News headline image
Why Exelixis Stock Trounced the Market on Thursday ↗
Via The Motley Fool
News headline image
Why Is Cancer-Focused Exelixis Stock Trading Higher On Friday? ↗
Exelixis reaffirmed its 2025 sales guidance of $2.15-$2.25 billion and reported sustained long-term efficacy for Cabometyx in advanced renal cell carcinoma. 
Via Benzinga
News headline image
Exelixis Announces a Newly Authorized $500 Million Stock Repurchase Program
From Exelixis, Inc.
Via Business Wire
News headline image
Don't overlook NASDAQ:EXEL—a stock with solid growth prospects and a reasonable valuation. ↗
NASDAQ:EXEL is scoring great on several growth aspects while it also shows decent health and profitability. At the same time it remains remains attractively priced. 
Via Chartmill
News headline image
Top 5 Biotech Stocks That Got Most Retail Buzz Last Week ↗
From merger updates to earnings surprises, these healthcare stocks saw the biggest spike in Stocktwits chatter. 
Via Stocktwits
News headline image
Bullish Setups ↗
You know things are bad when I stoop to offering some bullish setups, but that’s just where we’re at right now. 
Via Talk Markets
Topics Stocks / Equities
News headline image
Exelixis Announces Final Five-Year Follow-up Results from CheckMate -9ER Trial Evaluating CABOMETYX® (cabozantinib) in Combination with Opdivo® (nivolumab) in Patients with Advanced Kidney Cancer at ASCO GU 2025
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis to Participate in the Citi 2025 Virtual Oncology Leadership Summit
From Exelixis, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.